Pulse Electronics Corporation Common Stock PULS 深 滬
已收盤 12-12 16:00:00 美东时间
49.71
+0.010
+0.02%
華盛通- 最 高49.71
- 今 開49.70
- 成交量 329.33万股
- 最 低 49.70
- 昨 收 49.70
- 總市值 115.33亿
- 52周最高 49.71
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 47.3552
- 委 比 -35.96%
- 總股本 2.32亿
- 歷史最高 49.71
- 量 比 1.42
- 振 幅 0.02%
- 歷史最低 36.8914
- 每 手 1
- 風險率 0.72%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Johnson & Johnson MedTech VARIPULSE™ 平台将展示新数据
Johnson & Johnson MedTech专为房颤脉冲场消融术设计的一体化 VARIPULSE™ 平台的新临床及真实世界数据，将于 2025 年...
11-04 16:26
Boston Scientific announces results for third quarter 2025
MARLBOROUGH, Mass., Oct. 22, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.065 billion during the third quarter of 2025, growing 20.3 percent on a ...
10-22 18:30
Aptiv Unveils Gen 8 Radar For Hands-Free City Driving
Aptiv launches Gen 8 radars for advanced driver-assistance systems, with high-resolution sensing and enhanced perception in complex settings.
10-22 00:26
Pendle 收益策略全景解读：Pulse的AgentFi新范式
Pendle作为DeFi领域中首个专注于收益率拆分与交易的协议，通过创新的PT/YT代币机制，成功构建了收益型资产的“价格发现场所”，为加密资产的“收益率曲线”提供二级市场交易支持。其收益拆分机制将带收益的基础资产拆分为本金代币（PT）和收益代币（YT），用户可以通过PT锁定固定收益或通过YT进行收益投机和跨期套利。 在市场周期变化中，Pendle提供了差异化的策略，以满足不同风险偏好投资者的需求。牛市初期适合押注收益率上升，牛市亢奋期和熊市则更适合通过买入PT锁定高利率或在低利率环境下保值。震荡市时，跨期套利策略更具优势。 此外，Pendle还推出了Boros模块，将资金费率资产化，引入利率掉期、基差交易等传统金融衍生品工具，进一步丰富了策略维度。Pulse作为首个基于Pendle PT策略的AgentFi产品，实现了跨链固定收益场景的自动化优化，通过智能调仓和再平衡，最大化资金利用率和收益。
09-10 07:28
Novartis Sees Hope In Reducing Lifelong Treatment Burden For Autoimmune Blood Disorder
Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 immune thrombocytopenia trial.
08-12 21:43
Boston Scientific Reports Higher Profit Margins In Q2, Lifts Guidance
Boston Scientific beats Q2 estimates, posts 22.8% revenue growth, and raises full-year outlook on strong cardiovascular and MedSurg performance.
07-23 22:22
Novartis' Cosentyx Fails Late-Stage Giant Cell Arteritis Trial
Cosentyx missed its main goal in a Phase 3 GCA study, but showed lower steroid use. Novartis plans full review of the trial data.
07-03 21:00
Novartis' Fabhalta Delivers Hemoglobin Gains, Reduces Fatigue In Patients With Rare Blood Disorder
Novartis' Fabhalta improved hemoglobin, reduced fatigue and eliminated transfusion need in a Phase 3B PNH study presented at the 2025 EHA Congress.
06-13 02:25
首款阿尔茨海默病血液检测产品获FDA批准，开发商称下月在美上市
①美国FDA上周批准首款用于诊断阿尔茨海默病的检测试剂； ②检测过程便捷微创，费用仅为PET的一小部分，预计今年6月下旬在美国推出，并计划在多国提交审批。
05-20 21:30
Merck Presents New Clinical And Outcomes Research Data On Pulmonary Arterial Hypertension At ATS 2025 International Conference
Preliminary results from a pooled analysis of clinical trial data evaluating the long-term safety and favorable benefit-risk profile of WINREVAIR™ to be featured as a late-breaking presentationMerck (NYSE:MRK),
05-16 18:47
